PLX-4720

For research use only.

Catalog No.S1152

154 publications

PLX-4720 Chemical Structure

CAS No. 918505-84-7

PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 156 In stock
USD 120 In stock
USD 270 In stock
USD 477 In stock
USD 670 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's PLX-4720 has been cited by 154 publications

Purity & Quality Control

Choose Selective Raf Inhibitors

Biological Activity

Description PLX4720 is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM in a cell-free assay, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity for B-RafV600E than wild-type B-Raf.
Targets
C-Raf-1 (Y340D/Y341D) [1]
(Cell-free assay)
B-Raf (V600E) [1]
(Cell-free assay)
BRK [1]
(Cell-free assay)
B-Raf [1]
(Cell-free assay)
6.7 nM 13 nM 130 nM 160 nM
In vitro

PLX-4720 displays >10 times selectivity against wild type B-Raf, and >100 times selectivity over other kinases such as Frk, Src, Fak, FGFR, and Aurora A with IC50 of 1.3-3.4 μM. PLX-4720 significantly inhibits the ERK phosphorylation in cell lines bearing B-RafV600E with IC50 of 14-46 nM, but not the cells with wild-type B-Raf. PLX-4720 significantly inhibits the growth of tumor cell lines bearing the B-RafV600E oncogene, such as COLO205, A375, WM2664, and COLO829 with GI50 of 0.31 μM, 0.50 μM, 1.5 μM, and 1.7 μM, respectively. In addition, PLX-4720 treatment at 1 μM induces cell cycle arrest and apoptosis exclusively in the B-RafV600E-positive 1205Lu cells, but not in the B-Raf wild-type C8161 cells. [1] PLX-4720 treatment (10 μM) significantly induces >14-fold expression of BIM in the PTEN+ cells, compared with the PTEN- cell lines (4-fold), giving an explanation of the resistance of PTEN- cells to PLX-4720-induced apoptosis. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-4475 M4exSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoOwTWM2OD1yLkC3OFU4KM7:TR?= NXnRUFRNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
EoL-1-cell NUXnTnlkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMUSxOlYh|ryP MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
C32 NEHaOYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PhVmlEPTB;MD6xOVE{OSEQvF2= NIrK[Wg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
M14 NFvobFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF62WmhKSzVyPUCuNlE4PTdizszN NHviVII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
CP50-MEL-B NEfBXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGq5e4JKSzVyPUCuNlk4QDRizszN NGfISHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
A101D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLNVlRKSzVyPUCuN|I2QDlizszN Mn;OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
G-361 M4O3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXPbY1KSzVyPUCuN|Q3OzdizszN MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HT-144 NIq0OHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjTNWNvUUN3ME2wMlM3OzJ7IN88US=> NUjOOYY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
ACN M2qzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PY[mlEPTB;MD6zPFQ4PyEQvF2= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
COLO-829 NUmyS4hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHzTWM2OD1yLkO4PVY5KM7:TR?= MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
MEL-HO MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEK5RmJKSzVyPUCuOFEyPzlizszN MoOwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
SH-4 NGLpU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEe4RlBKSzVyPUCuOFE1OjJizszN MmHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
SK-MEL-3 M1XQOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfWeWY1UUN3ME2wMlUyPTZ6IN88US=> Moi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
A375 NV:xeFRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkCxTWM2OD1yLk[3N|U6KM7:TR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
MMAC-SF NXf0N5pOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVviW3FGUUN3ME2wMlY5PjF2IN88US=> NGLHbGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
BHT-101 NUT4cGhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELnZYFKSzVyPUCuO|A4ODJizszN M3myZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
K5 M3y2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zIOmlEPTB;MD63OlE1QCEQvF2= NInxeos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
BV-173 Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDJTWM2OD1yLke5OlQ1KM7:TR?= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
RVH-421 M2P1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7qcIZKSzVyPUCuPFY4QTZizszN MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HCC2218 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LL[mlEPTB;MD64O|g1PCEQvF2= NWjm[VgyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
WM-115 Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;Oc2lEPTB;MD64PFY6OiEQvF2= MnPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
SK-MEL-28 Mn7US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jIc2lEPTB;MT6wOFU3QSEQvF2= NXHUO5F1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
COLO-679 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxWIhKSzVyPUGuNVA1PjRizszN NX;D[FZLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
MZ7-mel NXfpfnl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PYNGlEPTB;MT6xOFk3OyEQvF2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SK-MEL-30 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1KxV2lEPTB;MT6zN|M5PiEQvF2= NXfJZ4tYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H209 M2PYZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PUT2lEPTB;MT62NFg3KM7:TR?= MoHKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HTC-C3 NX;OWFlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1e3[mlEPTB;MT62OlI6PCEQvF2= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
KARPAS-45 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJwMES5O|gh|ryP M1ize|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-SNU-5 M{PobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[ySGlEPTB;Mj6xNVk3QSEQvF2= NYHiTWZnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
KP-4 NYLlRZkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJwM{C3PFch|ryP M3f3PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
PA-1 NFXZR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;qU2lEPTB;Mj63NlY4OyEQvF2= MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HuO-3N1 M4TBT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS4TWM2OD1{Lki3PVQ3KM7:TR?= M3u2fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H358 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfDeXNKSzVyPUKuPVIzOzJizszN NWXtdnRvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
CTB-1 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrCdGVnUUN3ME2zMlQxOTd4IN88US=> MmjVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
697 NWrDTGNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjZOpBKSzVyPUOuOVUzPjZizszN NXm2W21LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
CP66-MEL MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzXSZRKSzVyPUSuNVU6OjdizszN Mof3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
NB13 NGr4NXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTRwNEmxO|kh|ryP MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
DBTRG-05MG MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPYTWM2OD12LkWzN|I2KM7:TR?= NGK5[pM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
A2058 NXzifGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3rR2pKSzVyPUSuO|IyPjRizszN NF\HUm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
KG-1 NGH4Z|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHG4RmVKSzVyPUSuO|M6ODhizszN NXL3cmkzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
8305C NUmzcW5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33HOGlEPTB;NT6xPFc{KM7:TR?= NFrnS2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
RPMI-7951 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DycGlEPTB;NT64NFI5OyEQvF2= NEPGeZM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
CHL-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnnUoNzUUN3ME21Mlk4PjB|IN88US=> MoT4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
TI-73 NXnsbYc3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILCbpJKSzVyPU[uNFA6ODJizszN M4fLTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
HT-1080 NETv[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHnTWM2OD14LkGwPVQ3KM7:TR?= NFrCOWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
ES5 M3XaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTZwMUS5NlQh|ryP MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
8-MG-BA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHvTWM2OD14LkG4NVI6KM7:TR?= M4rVdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NB7 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P2fWlEPTB;Nj6yNVM4OyEQvF2= NGT0dWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
H4 NXLjR5FkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTZwMkK0PVMh|ryP Mo\PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
CAL-72 NVrQTmFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTtTWM2OD14LkS1OFI{KM7:TR?= MofXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HCC1806 NWDUPFBOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DXe2lEPTB;Nj64NVk{OSEQvF2= M17SUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
BCPAP M2X6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHFTWM2OD15LkKxO|Y1KM7:TR?= MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
LB2241-RCC NF3ZXHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrvcXBKSzVyPUeuN|Y6ODdizszN NXn1TpVPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
COLO-741 Mlf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjZTHpKSzVyPUiuNFE3PzlizszN M{nSeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
HSC-3 M4WzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z2WmlEPTB;OD6wO|A3QCEQvF2= NUfLSGxIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SW982 M3nyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRThwNEG1NVYh|ryP MlHOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
GCT MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnUU3RQUUN3ME24Mlc2OzF2IN88US=> NXPPSZBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
KY821 NEG0W2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTlwMEWxO|gh|ryP M1nlXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
JVM-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTlwNU[5PVkh|ryP Mn3IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
RS4-11 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrhZmMyUUN3ME25MlYxPDhizszN NH;UN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
VA-ES-BJ NVSzTIJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlv1TWM2OD1zMD6wNVQ6KM7:TR?= NHPnN|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
A431 M2Ltc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFyLkSyNVIh|ryP NYPCcFY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
LXF-289 M4nhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjpUpp1UUN3ME2xNE41PThizszN MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SK-MEL-24 M3HLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jrbmlEPTB;MUCuPFI4PCEQvF2= NVjlbnVvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NOS-1 NGLxS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXDWnVKSzVyPUGwMlg1PzJizszN NUDlcVdlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
KNS-62 NX;0Z5RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFzLkK0NFQh|ryP NX;YNFh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SK-HEP-1 NVr5c2g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTFzLkO1Nlch|ryP M3zuW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
A3-KAW NGH6N5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFzLkexO|gh|ryP MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
SK-LU-1 NFjSNWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTF{LkK2OVUh|ryP NUnHeop{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
TYK-nu M{DV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfqUpI4UUN3ME2xNk4{QTN{IN88US=> NHTQboU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
NMC-G1 Mo\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTF{Lk[wOlIh|ryP M3LjSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
BB65-RCC MoDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLYU|FKUUN3ME2xNk44OTZ7IN88US=> NYGydppKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
QIMR-WIL MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXhW4pKSzVyPUGyMlg5OzNizszN NVjoTGxWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
D-566MG M{LDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jUVGlEPTB;MUOuPVU4PiEQvF2= NHjkWYg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
KYSE-140 NHm5NmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF2LkC3OVMh|ryP MmPzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
SCC-4 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInId4VKSzVyPUG0MlM{PTlizszN NEHWZlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
U251 NXixc2h3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1GyPWlEPTB;MUSuPFQ6OiEQvF2= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
D-542MG NGCycXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHj4dpBKSzVyPUG0MlkzOjJizszN NIPuXlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
LAMA-84 Mk\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\ETWM2OD1zND65PVMzKM7:TR?= NYDUeIR2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H720 M2LzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTF3LkK2PFQh|ryP M3jn[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
DEL NFSxZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LidGlEPTB;MUWuOFI6OyEQvF2= NXLxfHV5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
SBC-1 MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF3LkSzNFUh|ryP NEjNR2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
ECC10 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF3LkS0OVgh|ryP NWrC[WN2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
Daoy NGLWSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXO[o9KSzVyPUG1Mlc3OTZizszN MnziQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
SCH NEK4WZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTF3Lke4N|Uh|ryP NWqxPIRGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
MZ2-MEL MlHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7zTWM2OD1zNj6wOlQ3KM7:TR?= M363XVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
CAL-12T NXP0b2V6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjyTWM2OD1zNj60PFYzKM7:TR?= Mlu2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
KE-37 NXvhWHkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTF4LkixNFch|ryP M1u0PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LS-411N MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTF5LkGxPEDPxE1? M3rKUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H2228 M4\NTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\MOnJKSzVyPUG3MlMxPzFizszN M4XrWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
SK-MEL-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF5LkS5OlUh|ryP MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HN MnLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWn3eI5WUUN3ME2xO{44OjR6IN88US=> MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-H1648 NVvC[YY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTyN|JCUUN3ME2xO{45OThizszN MlTTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
IA-LM MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTF6LkOxO|Ih|ryP Mn3CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
EW-13 NWrlWWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPtPVZNUUN3ME2xPE42PzB6IN88US=> MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
YKG-1 M2HZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\sSWlEPTB;MUmuOVcyOSEQvF2= NHPsXmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
KNS-81-FD NXfVOlg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTF7LkW4OVgh|ryP MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
23132-87 NYHNT4JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV23fXU3UUN3ME2xPU44PjR{IN88US=> MlvUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
NUGC-3 NF7wWmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;UTWM2OD1zOT65PFg4KM7:TR?= NGG5TnM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
5637 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJyLkC0O|gh|ryP M4TBO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H1755 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjofWFuUUN3ME2yNE41PzZ2IN88US=> M1rt[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
RH-18 NV;tfWMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrw[o9[UUN3ME2yNE42PzR6IN88US=> NGDr[ms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
RXF393 MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfseZpKSzVyPUKwMlY4PTZizszN Ml3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LU-134-A NYC5UWllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;CTWM2OD1{MD63NFU3KM7:TR?= NUG1bJIzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
TE-12 M1;nUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPBZo44UUN3ME2yNE44OjBzIN88US=> MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
MOLT-4 M2LYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPrclZKSzVyPUKxMlE6OTVizszN M4SzTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
IGR-1 M3HXcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2qzVWlEPTB;MkGuN|c6PiEQvF2= MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
HOP-92 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHK1Z4ZKSzVyPUKxMlQ6QDdizszN NH3YV3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
SK-MES-1 NIfTNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXPTWM2OD1{MT63N|gyKM7:TR?= NX\ZRldERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
LU-65 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDQeXNKSzVyPUKxMlg3OjRizszN MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
MS-1 Mny4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;vV2lEPTB;MkKuNVIxOyEQvF2= MkDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
LoVo NYPXSo5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljkTWM2OD1{Mj6yOFQh|ryP NInOc4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
A704 M3TyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULPcGxLUUN3ME2yNk42OTV3IN88US=> MkLtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HT-1376 M1;ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3J[2tLUUN3ME2yNk43ODV7IN88US=> Moq0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
IST-MEL1 MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTJ{Lk[3OVEh|ryP NHfEeFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
Ramos-2G6-4C10 M{PUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYj4PG1lUUN3ME2yNk44OzZ4IN88US=> MorYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
T47D MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnhWIZ[UUN3ME2yNk44QTd7IN88US=> NGXIdJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HT-1197 NEnsTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXJcXRxUUN3ME2yN{4xQDF5IN88US=> NXS0OYNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
LB2518-MEL Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ|Lk[0NVIh|ryP NF[5b|c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
J-RT3-T3-5 NWLzc3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTJ2Lke1PVUh|ryP NF;4dVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
SK-NEP-1 M2PXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL0VXJ3UUN3ME2yOE45PzR2IN88US=> NUnybpJyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H526 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFq4ZmtKSzVyPUK1MlAxOjNizszN M{K0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
IST-SL1 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\kU5JVUUN3ME2yOU4zPzVzIN88US=> NUfJS4szRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
HH NVvMc21iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2KwSWlEPTB;MkWuN|E6OiEQvF2= NUPwWG5iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
NCI-H82 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTJ3LkmzPEDPxE1? M2PNd|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
SNU-449 NX2zRpRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3LUFFKSzVyPUK3MlIxOThizszN NE\wfmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
COR-L23 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnm1TWM2OD1{Nz6yPFE{KM7:TR?= NIPKdXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
LOXIMVI M1rvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTmTWM2OD1{Nz6zOlgh|ryP NF\5SHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
GR-ST NX;JUZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnRfZdKSzVyPUK3MlY4ODZizszN MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-SNU-1 NVXVTXVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3VcIJ1UUN3ME2yO{46PDRizszN MlO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
ALL-PO NGXIW5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7XbXdKSzVyPUK4MlE3ODRizszN M1raTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
ML-2 MmHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDqTWM2OD1{OD6yPFE1KM7:TR?= M1mxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
HOP-62 MoS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37O[GlEPTB;MkiuO|E{KM7:TR?= Mlv0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
EGI-1 M{fPeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTJ6Lki4OFUh|ryP MmfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
TCCSUP M2[zTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILWfplKSzVyPUK4MlkzPzJizszN NFXKfYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
LB996-RCC NIfyfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXvSW9KSzVyPUK5MlU3QDJizszN M1[2e|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LCLC-97TM1 M4DjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\pZXhKSzVyPUOyMlE6PjRizszN MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-H1304 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN{LkOzNFEh|ryP Mnn6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
KP-N-YS MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjBUotLUUN3ME2zNk42QTd|IN88US=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
NCI-H1770 NGHuN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTiZmVKSzVyPUOzMlE3PDhizszN NWX4PG86RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
EM-2 Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;pcGlEPTB;M{OuOlUxPCEQvF2= NXfJNY9PRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
ChaGo-K-1 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\tT2d6UUN3ME2zN{44OjN4IN88US=> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
ACHN NUW5WY1kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT4XGJpUUN3ME2zN{45Ozh3IN88US=> MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
MN-60 NVXSVmk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFS0SHdKSzVyPUOzMlg2PDRizszN M3TucVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
EW-18 NV\l[VQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPiZnd[UUN3ME2zN{45QTdzIN88US=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
KGN MlL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo[0TWM2OD1|NT63NlkzKM7:TR?= NELUd|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
U031 NY\UdXFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGeyUHZKSzVyPUO1MlgyOzJizszN NIjNSYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HMV-II MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;xU5ZKSzVyPUO2MlA4PzRizszN NWi4[FBbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
L-363 NHrl[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\vTWM2OD1|Nz62OFU2KM7:TR?= M3PGeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H1155 NX75NWJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPmTWM2OD1|OD6wNFE2KM7:TR?= M3qydlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
NCI-H1793 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfMTWM2OD1|OD6xNFI3KM7:TR?= MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
P30-OHK Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTrN3JPUUN3ME2zPE4yOzN{IN88US=> M3XOV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
AN3-CA MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Dl[GlEPTB;M{iuNVYyPSEQvF2= NVHpZoNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
UACC-257 MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHnW4Z3UUN3ME2zPE44QSEQvF2= NEW5TXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
MCF7 MkXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PO[GlEPTB;M{muPFYzQSEQvF2= NH3BWIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
KP-N-YN NVW0W4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPPTWM2OD12MD60Nlg2KM7:TR?= MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
T98G MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorDTWM2OD12MD60PVU4KM7:TR?= NEjNZW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HGC-27 M4PDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR|LkK3OEDPxE1? NETtN5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
NCI-H1092 NUXBUGMzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfMV3g4UUN3ME20N{4zQDl3IN88US=> NEXPPGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
KARPAS-299 MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\HTWM2OD12Mz6zNFcyKM7:TR?= M{Doc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LB1047-RCC NHXvWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTR2Lkm5OVkh|ryP NUTVU5FNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
786-0 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\tTWM2OD12NT62OUDPxE1? NIr5VWs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
HCC2157 M4fuVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n4dGlEPTB;NE[uNFM2QSEQvF2= NFLqOIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
NY NF7se3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPQTWM2OD12Nj6xO|c5KM7:TR?= NEXzXWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
EFM-19 MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTR4Lke1N|Mh|ryP MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
EW-16 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ITWM2OD12Nj63PFA3KM7:TR?= NWXhUFJtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
UM-UC-3 M{fITWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTR4LkiwOVkh|ryP MoLEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
HT-29 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3GxZ2lEPTB;NEeuPFc6OiEQvF2= M13D[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFEzOzByMkCvK|5USU6JRWK8M4E,
LN-405 NHf5dFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnvTWM2OD12OD6wPFI4KM7:TR?= NGLOfHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyOjNyMEKwM{c,W0GQR1XSQE9iRg>?
NCI-H727 NWDHWIlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TM[mlEPTB;NEiuO|czPiEQvF2= MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
D-502MG M17xRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK3bpBKSzVyPUS4Mlk3PzZizszN MoXzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVI{ODB{MD:nQnNCVkeHUkyvZV4>
GMS-10 M3LNSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjDTWM2OD12OT6yPVc1KM7:TR?= MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxNlMxODJyLze+V2FPT0WUPD;hQi=>
MEL-JUSO MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLWb|BnUUN3ME20PU4{PDdizszN NXvKS4FORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTJ|MECyNE8oRlODTlfFVlww[T5?
insect cells M4LuTmZ2dmO2aX;uJIF{e2G7 M4raWGlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZMufGGpZ3XkJGJTSUZiVk[wNGUhdXW2YX70JEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKGKjY4Xsc5ZqenW|IHnu[oVkfGWmIHnud4VkfCClZXzsd{Bkdy2neIDy[ZN{cW6pIFPER|M4KHW|aX7nJIJqd3SrbonsZZRm\C2PRVugZZMhe3Wkc4TyZZRmKGK7IFHsdIhiW2O{ZXXuJIF{e2G7LDDJR|UxKD1iMD6wNVMh|ryPLh?= NVXsRmRkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0OlE5OjdpPkK5OFYyQDJ5PD;hQi=>
A375 MkS5SpVv[3Srb36gZZN{[Xl? NIHjN|NKdmirYnn0bY9vKG:oIFLSRWYhXjZyMFWgcZV1[W62IHnuJIh2dWGwIFGzO|Uh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIFXST{BxcG:|cHjvdplt[XSrb36gZpkhSWyyaHHTZ5Jm\W5iYYPzZZktKEmFNUCgQUAxNjB2NDFOwG0v MkX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2NkG4NlcoRjJ7NE[xPFI4RC:jPh?=
A375 NV\NNpU6TnWwY4Tpc44h[XO|YYm= NH;sTW1KdmirYnn0bY9vKG:oIHKtVoFnKGmwIHj1cYFvKEF|N{WgZ4VtdHNiYYPz[ZN{\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXST{whUUN3MDC9JFAvODR4IN88UU4> Ml7sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEi5NVEoRjJ{OEC4PVEyRC:jPh?=
A375 NFzwZYVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= Mnf6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHX4dJJme3OrbnegRk1T[WZiVk[wNGUhdXW2YX70JIFv\CC5aXzkJJR6eGViUnHzMEBKSzVyIE2gNE42KM7:TT6= MlW2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEi5NVEoRjJ{OEC4PVEyRC:jPh?=
A375 M1\zTmN6fG:2b4jpZ4l1gSCjc4PhfS=> NH;U[|A4OiCqcoO= NEfO[phEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOzd3IHPlcIx{KGijcnLvdolv\yCEUlHGJHY3ODCHIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiSVO1NEA:KDBwNTFOwG0v M{XpfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NE[xPFI4Lz5{OUS2NVgzPzxxYU6=
HCT116 MnnsRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NYfMc2xKSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViYj3SZYYh[W6mIFvSRXMhdXW2YX70MEBKSzVyIE2gNlch|ryPLh?= MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyOEmxNUc,OjJ6MEi5NVE9N2F-
A673 MXTxTHRUKGG|c3H5 MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? MlPtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 Mo[wdWhVWyCjc4PhfS=> M4C3NJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= NHPWPHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD MoLZdWhVWyCjc4PhfS=> MnnFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NIPHUFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-SH M4nHT5FJXFNiYYPzZZk> NHjBe5lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=> M17U[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643 MUXxTHRUKGG|c3H5 NGnNV5NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz NV;Oe3dHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50 M4TNU5FJXFNiYYPzZZk> M2nHfZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 MlPTdWhVWyCjc4PhfS=> MWXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?= NEfDNmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC NVnVfY5WeUiWUzDhd5NigQ>? M3nmSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NVzKc49MRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-MEK / MEK / p-ERK / ERK / p-FAK(S910); 

PubMed: 23076151     


WM793 and WM793-Res NRAS cells were seeded overnight in the absence of PLX4720 and then treated with 1 μm PLX4720 for times ranging from 0 to 24 h. Samples were analyzed by Western blotting for phospho-MEK, total MEK, phospho-ERK1/2, total ERK1/2, phospho-S910 FAK, and total FAK.

p-EGFR 1173 / EGFR / p-Akt / Akt; 

PubMed: 26023796     


Three BRAF(V600E) glioma cell lines, NMC-G1, AM38 and DBTRG-05MG were subjected to a 24 hour time course treatment with 5 μM PLX4720 in the presence or absence of 1 μM HKI-272. These cells were serum starved for 16 hours before being stimulated with 10% FBS and harvested for immunoblotting analysis. Cells treated with PLX4720 alone showed an initial suppression of MEK and ERK phosphorylation followed by a profound rebound of MAPK pathway activation as early as one hour post-PLX4720 treatment. Elevated levels of EGFR phosphorylation were also observed in the PLX4720 treated cells. The extent of Akt phosphorylation increased upon PLX4720 treatment, although the extent varies between cell lines. In contrast, no reactivation of EGFR, MEK, ERK or Akt was observed in cells pre-treated with HKI-272.

p27 / Cyclin D1 / pRb; 

PubMed: 21828154     


Immunoblot analysis revealed that PLX4720 (3 μM) decreased levels of phosphorylated ERK, decreased levels of cyclin D1, increased levels of p27, and decreased levels of phosphorylated Rb in BRAF-mutant (OCM3) cells. On the contrary, in Gα-mutant (OMM1.3) UM cells, PLX4720 induced a paradoxical increase in phosphorylated ERK and Rb levels and an early increase in cyclin D1 levels but did not stimulate p27 levels.

pAkt(Ser473) / pAkt(Thr308); 

PubMed: 21828154     


Immunoblot analysis revealed that both AZD6244 and PLX4720 induced an early (within 2–6 hours of exposure) increase in the levels of phosphorylated Akt (at residues Ser473 and Thr308) in both BRAF-mutant OCM3 and Gα-mutant OMM1.3 cells. Eventually, and with prolonged drug exposure, the phosphorylation of Akt returned to baseline in Gα-mutant OMM1.3 cells and decreased even below baseline levels in BRAF-mutant OCM3 cells.

23076151 26023796 21828154
Immunofluorescence
LAMP1; 

PubMed: 30979895     


Representative images of LysoTracker Red (red) and LAMP1 (green) immunostaining of PLX4720 (1 μM, 12 h-treated) A375 cells with depletion of the indicated genes. Note the reduced lysosome staining in PLX4720-treated cells upon TFEB depletion. 

ZKSCAN3 / TFEB ; 

PubMed: 30979895     


Representative confocal images of subcellular translocation of endogenous TFEB (green) and ZKSCAN3 (red) in A375 cells treated with PLX4720 (1 μM, 12 h). n = 3 independent experiments. 

30979895
Growth inhibition assay
Cell viability; 

PubMed: 27848137     


AM-38 and DBTRG-05MG cells were treated for 5 days. Media was changed once every 3 days. Cell viability was measured using WST-1 assay. Error bars indicate the variation between triplicate measurements. PLX4720 and PD0325901 alone or in combination reduced cell viability significantly. However, combined therapy led to the most significant cell viability reduction compared to either monotherapy in both AM-38 and DBTRG-05MG cell lines.

27848137
ELISA
mIFN-γ; 

PubMed: 23204132     


(C, D and E) IFN-γ secretion by pmel-1 T cells co-cultured with transduced melanoma cells (after cell sorting) that had been pre-treated with the indicated concentrations of PLX4720, as determined by ELISA. (*P<0.05, ** P<0.01) Data are representative of 3 independent experiments.

23204132
In vivo Oral administration of PLX-4720 at 20 mg/kg/day induces significant tumor growth delays and regressions in B-RafV600E-dependent COLO205 tumor xenografts, without obvious adverse effects in mice even at dose of 1 g/kg. PLX-4720 at 100 mg/kg twice daily almost completely eliminates the 1205Lu xenografts bearing B-RafV600E, while has no activity against C8161 xenografts bearing wild-type B-Raf. The anti-tumor effects of PLX-4720 correlate with the blockade of MAPK pathway in those cells harboring the V600E mutation. [1] PLX-4720 treatment at 30 mg/kg/day significant inhibits the tumor growth of 8505c xenografts by >90%, and dramatically decreases distant lung metastases. [3]

Protocol

Kinase Assay:[1]
- Collapse

In vitro Raf kinase activities:

The in vitro kinase activities of wild type Raf and mutants are determined by measuring phosphorylation of biotinylated-MEK protein using Perkin-Elmer's AlphaScreen Technology. For each enzyme (0.1 ng), 20-μL reactions are carried out in 20 mM Hepes (pH 7.0), 10 mM MgCl2, 1 mM DTT, 0.01% Tween-20, 100 nM biotin-MEK protein, various ATP concentrations, and increasing concentrations of PLX-4720 at room temperature. Reactions are stopped at 2, 5, 8, 10, 20, and 30 minutes with 5 μL of a solution containing 20 mM Hepes (pH 7.0), 200 mM NaCl, 80 mM EDTA, and 0.3% BSA. The stop solution also includes phospho-MEK Antibody, Streptavidin-coated Donor beads and Protein A Acceptor beads from the AlphaScreen Protein A Detection Kit. The antibody and beads are preincubated in stop solution in the dark at room temperature for 30 minutes. The final dilution of antibody is 1/2,000, and the final concentration of each bead is 10 μg/mL. The assay plates are incubated at room temperature for one hour then are read on a PerkinElmer AlphaQuest reader.
Cell Research:[1]
- Collapse
  • Cell lines: COLO205, A375, WM2664, COLO829, HT716, SW620, H460, Calu-6, HCT116, SK-MEL2, SK-MEL3, Lovo, H1299, 1205Lu, and C8161 cells
  • Concentrations: Dissolved in DMSO, final concentrations ~1 mM
  • Incubation Time: 24, 48, and 72 hours
  • Method: Cells are treated with various concentrations PLX-4720 for 24, 48, and 72 hours. Cell proliferation is measured by using the CellTiter-Glo Luminescent Cell Viability Assay or MTT assay. For cell cycle analysis, supernatant and cells are collected, pelleted, and fixed with 70% ethanol. Before staining with propidium iodide (10 μg/mL), cells are incubated for 1 hour at 37 °C in 0.5 mg/mL RNase I to rid samples of residual RNA contamination. Samples are then analyzed by using the EPICS XL apparatus. For the assessment of apoptosis, media and cells are harvested and pelleted before staining with annexin-FITC and propidium iodide. Samples are subsequently analyzed by using the EPICS XL apparatus.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female athymic mice (NCr nu/nu) implanted s.c. with COLO205 cells, and SCID mice with 1205Lu or C8161 cells
  • Dosages: 5, 20, or 100 mg/kg
  • Administration: Oral gavage once or twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+50% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.83
Formula

C17H14ClF2N3O3S

CAS No. 918505-84-7
Storage powder
in solvent
Synonyms N/A
Smiles CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)Cl)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What would you recommend to make working solution for intraperitoneal injection into mice?

  • Answer:

    PLX4720 has very limited solubility in aqueous solution and for this reason, we recommend oral gavage to administer this compound as not fully dissolved suspension can be used in oral gavage feeding.

Raf Signaling Pathway Map

Raf Inhibitors with Unique Features

Related Raf Products

Tags: buy PLX-4720|PLX-4720 ic50|PLX-4720 price|PLX-4720 cost|PLX-4720 solubility dmso|PLX-4720 purchase|PLX-4720 manufacturer|PLX-4720 research buy|PLX-4720 order|PLX-4720 mouse|PLX-4720 chemical structure|PLX-4720 mw|PLX-4720 molecular weight|PLX-4720 datasheet|PLX-4720 supplier|PLX-4720 in vitro|PLX-4720 cell line|PLX-4720 concentration|PLX-4720 nmr|PLX-4720 in vivo|PLX-4720 clinical trial|PLX-4720 inhibitor|PLX-4720 MAPK inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID